\r\n\tTo this end, erectile dysfunction affects the health, well-being and quality of life of the affected person. Perhaps, due to cultural reasons, most of them feel great unease to seek medical care in spite of the overwhelming need to do so. Some of them have yet to understand that their suffering is a medical condition. In most cases, a hospital visit is usually encouraged and sometimes pressured by the spouse or partner.
\r\n\tFrom available studies, a number of factors can cause erectile dysfunction, including, general medical conditions, emotional disturbance and psychiatric disorders. However, more researches on the subject are expected and bigger is the need of people to be adequately health-informed and educated about the condition.
\r\n\tThis book is a compilation of the state-of-the art overview on erectile dysfunction. The book equally intends to provide the reader with comprehensive understanding and overview of the current trends about erectile dysfunction.
Salicylic acid (SA) in plants is a ubiquitous compound shown to be pivotal in initiating the response to a variety of physical, chemical and biological insults [1]. Analgesic and antipyretic properties of plant extracts, notably from willow, meadowsweet and myrtle, had been known for many centuries before isolation of SA as the active principle. Since synthesis of its acetyl ester—aspirin—investigation has focused on the properties of that compound which is rapidly hydrolysed (serum t\n1/2 of 20 min) to SA which itself has a half-life of 2–4 h [2]. The demonstration that aspirin works by serine side chain acetylation of Cox-1 and Cox-2 isoforms has detracted attention from SA itself; that compound, despite weak reversible Cox 1 and absent Cox 2 inhibition, is as effective as aspirin in vivo in suppressing inflammation [3]. Inhibition of transcription of the Cox-2 gene by micromolar concentrations of SA is the likely explanation [4].
\nInvestigating the possible use of low dose aspirin as an aromatic probe to measure hydroxyl free radicals by assessing the hydroxylation of SA to form 2,3 and 2,5 dihydroxybenzoic acids (DHBAs)—Figure 1—required a sensitive HPLC assay with appropriate controls. That work revealed the presence of substances which had identical retention times to SA, 2,3 DHBA and 2,5 DHBA in the serum extracts of subjects not taking aspirin. The exclusion of contamination was followed by studies to determine the authenticity of these substances as SA, 2,3 DHBA and 2,5 DHBA.
\nMetabolism of aspirin, salicylic acid and benzoic acid. (1) acetylsalicylic acid (aspirin); (2) salicylic acid; (3) salicyluric acid; (4) 2,5 dihydroxybenzoic acid; (5) 2,3 dihydroxybenzoic acid; (6) 2,3,5 trihydroxybenzoic acid; (7) benzoic acid; and (8) hippuric acid.
Examination of the chromatograms of blank serum or plasma from published methods of SA analysis revealed the presence of an unknown substance with a retention time (Rt) similar to SA [5, 6]. While Ruffin et al. [7] reported SA in the plasma from 17 of 53 subjects at baseline there was no information as to how they confirmed identification of the compound.
\nWe examined samples from drug free volunteers: extracts of acidified serum were analysed by high performance liquid chromatography (HPLC) with electrochemical detection. Chromatographic conditions were altered and the Rts of the unknown compounds compared against authentic SA, 2,3 DHBA and 2,5 DHBA. Serum samples (some spiked with SA) were also incubated with a bacterial salicylate hydroxylase and the substance which had a Rt identical to SA disappeared. Finally the trimethylsilyl (TMS) derivative of the unknown and SA had, using gas chromatography–mass spectrometry (GC–MS), a similar retention time and total ion chromatogram [8].
\nArmstrong et al. [9] had detected, by paper chromatography, a compound with characteristics similar to those of SU in the urine of 400 people who had not taken salicylate drugs. That was in an admixture of 49 compounds of predominantly, it was suggested, dietary origin. Von Studnitz and colleagues, who also used a paper system, suggested SA might be one of the phenolic acids in the urine of subjects on a diet restricted to glucose and citric acid [10]. Young reported a compound with thin layer chromatographic properties of SU [11] in a single individual on a synthetic diet, while Finnie and co-workers found a similar compound on their paper system in children not taking salicylate drugs [12]. At the time of all these earlier investigations methods for adequately characterising and quantifying the purported SA and SU were not readily available.
\nOther work [13] designed to assess the dietary importance of salicylates had examined acid-treated urine using HPLC with fluorescence detection but salicylates other than SA, salicylate precursors and structurally related compounds may have been included in the values reported.
\nWe examined 24 h urine samples from 10 volunteers who had not taken any salicylate drugs during the previous 2 weeks. The acid hydrophobic compounds (=organic acids) were separated using HPLC and quantified electrochemically. The Rts of the extracted substances and those of SA and SU were compared under two sets of chromatographic conditions and found very similar to those of authentic substances. The unknown substances, isolated by HPLC, and treated with acetyl chloride in methanol were compared with the methyl esters of SA and SU using GC–MS. After esterification the unknown compounds had mass spectra and Rts comparable to those of methyl-SA and methyl-SU [14].
\nThese findings in serum and urine led us on to explore, in some detail, the likely dietary sources for the salicylate compounds we found and confirmed. At the time interest was re-awakening in the potential benefits of salicylates commonly found in the diet [13]—as opposed to what were considered traditional plant medicine sources.
\nThe occurrence of “natural salicylates”, such as SA, in strawberries and other fruits was raised in the Lancet in 1903 [15] and the matter of whether these natural salicylates were superior to synthetic salicylates was the subject of a JAMA editorial in 1913 [16]—no superiority was concluded! Interest then appeared to wane until re-invigorated by the popularity, from ∼1970, in therapeutic trials—arising from the apparent cross-reactivity of tartrazine and aspirin—of exclusion diets.
\nMany plant derived non-nutritive compounds exert, in mammalian systems, biological activities that may have an impact on health and disease risk [17] and we proposed [18] that SA might provide a link between aspirin, diet and the prevention of colorectal cancer (CRC). There is good evidence that the regular intake of aspirin decreases the risk of developing cancer [19]. A mechanism for platelet mediated CRC tumorigenesis has been proposed [20]; that would, of course not be attributable to SA itself but a more balanced view is that both constituent groups of aspirin (acetyl and SA moieties) contribute to the anti-cancer effects [21].
\nAssessment of the extent of the contribution of diet to SA in blood and urine cannot be easily inferred from direct analysis of its concentration therein. There is considerable variability in peak serum levels of SA in subjects receiving a standard dose [7] while urinary salicylate is influenced by urine flow, pH, the presence of other organic acids and the saturability of SU formation and/or excretion [2].
\nIt was unclear whether sufficient salicylic acid could be obtained from dietary sources to influence health and disease with estimated daily intakes ranging from 0.4 to 200 mg/day [13, 22, 23]. That range reflected the disparate information available on the salicylate content of foods.
\nComparison, in the serum of subjects not taking aspirin, of SA levels in 37 vegetarians and 39 non-vegetarians found higher concentrations in the former [24]. That study revealed median concentrations of 0.11 (range 0.04–2.47) μmol/L and 0.07 (range 0.02–0.20) μmol/L respectively: the median of the difference was 0.05 μmol/L (95% confidence interval for difference 0.03–0.08; p < 0.0001). The median SA level measured in serum from 14 patients on aspirin 75 mg/day was, at 10.03 (range 0.23–25.40) μmol/L, significantly higher. However there was overlap in serum SA concentrations between the vegetarians (8 higher than lowest low dose aspirin) and patients taking aspirin (6 below the highest vegetarian value). These findings should be considered in light of the inhibition of COX2 transcription that has been shown to occur at SA levels as low as 0.1 μmol/L [4].
\nIn a further study the urinary excretion of SA and SU was assessed in 24 h samples from 27 non-vegetarians, 21 vegetarians and 40 patients taking 75 or 150 mg aspirin/day [25]. For SU, the principle urinary salicylate, vegetarians excreted significantly more than the non-vegetarians (median 11.01; range 4.98–26.60 μmol/24 h compared with 3.91; range 0.87–12.23 μmol/24 h) but these amounts were significantly lower than those excreted by patients on aspirin. Significantly more SA was excreted by the vegetarians (median 1.19; range 0.02–3.55 μmol/24 h) than by the non-vegetarians (median 0.31; range 0.01–2.01 μmol/24 h). The median amounts of SA excreted by the vegetarians and the patients taking aspirin were not significantly different. These values were comparable to those found earlier, using less specific methodology, in a group of drug free volunteers on a variety of diets [13].
\nAwareness that certain spices had been reported [22] to contain especially high concentrations of SA and the reported very low incidence of colorectal cancer in rural India [26] led to our particular assessment of spices.
\nSpices, Indian cooked dishes and blood and urine samples taken after ingestion of a test meal were investigated for their salicylate content. Total salicylate content determination required a preliminary alkali treatment step before our standard extraction [27] as, in plants, phenolic glycosides and carboxylic esters are present as well as the “free” phenolic acid. Our standard assay conditions for SA were then applied. All samples of spices and cooked meals examined contained SA (up to 1.5 wt%); cumin, turmeric, red chilli powder, paprika and cinnamon were especially rich sources. Our measurements were considerably higher than those previously published [22]. That was attributed to previously suboptimal extraction, chromatographic separation and detection [27]. The identity of the SA fractions (on HPLC) from cumin, paprika and turmeric was confirmed, after elution and esterification, by GC–MS of their methyl esters.
\nThe potential bioavailability of SA derived from a prepared meal was assessed in a single aspirin free volunteer after a 10 h fast. Consumption of 545.3 g of a cooked vegetable dish (shown by aliquot assay to contain 94.03 g of total salicylates) was followed by regular blood and urine collection over 6 h. Serum SA doubled within 1.5 h and urinary SU increased ∼20-fold during that time.
\nNative Indian volunteers, living in a rural area near Chennai, had been recruited for another study as representative of that community for health lifestyle and nutritional status. They had a diet of locally grown vegetables, grains and pulses flavoured with spices and herbs. The serum from these 21 South Indians had a median SA concentration of 0.263 μmol/L (range 0.05–0.64—significantly higher (∼2.5- to 3.5-fold higher) than those found in the sera of the other groups reported above [24]; p < 0.001 against both vegetarians and non-vegetarians by Mann–Whitney U test) [27]. Summarised and compared with other results below in Table 1.
\n\n | Median (μmol/L) | \nRange (μmol/L) | \n
---|---|---|
Vegetarians n = 37 | \n0.110 | \n0.04–2.47 | \n
Non-vegetarians n = 39 | \n0.070 | \n0.02–2.00 | \n
Southern Indian villagers n = 21 | \n0.263 | \n0.05–0.64 | \n
75 mg aspirin takers n = 14 | \n10.03 | \n0.23–25.4 | \n
Given that SA is a stress hormone in plants we can anticipate that locality, varietal and growing conditions could affect total salicylate content at harvesting before any variability in processing conditions and storage effects. Wide reported ranges for different brands assayed using standard conditions are therefore not particularly surprising. For example the SA content of five brands of orange juice obtained from Scottish retailers ranged from 0.47 to 3.01 mg/kg [29].
\nUsually an open question but, given the above considerations, probably not in respect of SA content. Thus the median SA contents in organic and non-organic vegetable soups were 117 ng/g (range 8–1040) and 20 ng/g (range 0–248) respectively; the median between the difference groups was 59 ng/g (95% confidence intervals 18–117 ng/g), p = 0.032 by Mann Whitney U test [30]. Consider also constraints of drought, other physical stresses and non-availability of pest control which inevitably prevail in many emergent nations.
\nClearly sample selection and methodology will affect estimates of SA content in the diet. Using the assay methodology our group developed [27, 30] to supplement published results, Wood et al. [29] prepared a comprehensive dietary database. They filtered published results of dietary constituent total salicylate content by specific criteria. Food items had to be randomly selected and purchased from various commercial outlets at different times of the year; food samples to be prepared using standard domestic practices; optimised sample extraction and hydrolysis conditions were to be clearly described or cited, and salicylate determination to be based on modern techniques of HPLC and mass spectrometry with validation and quality assurance methods summarised. Combination of such published data, which met these criteria, together with their in-house analyses resulted in a database of 27 types of fruit, 21 vegetables, 28 herbs, spices and condiments, 2 soups and 11 beverages—expressed as median values to reflect the non-normal distribution of the results.
\nSubsequently dietary intake was assessed by applying this salicylate database, using a validated questionnaire, to 237 healthy individuals age range (17–72) from Aberdeen [29]. Estimated median total salicylate intakes for men and women were 4.42 and 3.16 mg/day respectively, a gender difference not sustained when corrected for energy. Primary food sources of salicylates as shown in Figure 2 were alcoholic beverages (22%), herbs and spices (17%), fruits (16%), non-alcoholic beverages including fruit juice (13%), tomato-based sauces (12%) and vegetables (9%). Salicylate intake was significantly (p < 0.001) and positively associated with intakes of fibre, potassium, vitamin C and alcohol!
\nRelative contributions of different food groups to total salicylate intake of a Scottish population. Source: [29].
There were clear suggestions in the literature that SA and SU in urine might not all derive from diet, given their presence in the urine of subjects on restricted diets [9, 11]. In addition quantification of the contribution from fruit and vegetable consumption to circulating SA levels in man had demonstrated, using a sensitive and specific method that <20% of the variability derived from these sources [31]. So some circulating SA in aspirin-naïve or -free individuals may derive from other dietary sources or be of non-dietetic origin.
\nBlood samples, serum or plasma, were obtained from animals at London Zoo or the Department of Biological Services, University of Glasgow in accordance with their approved codes of practice. The results (Table 2) showed that species regarded as primarily carnivorous had blood SA levels comparable to those measured in herbivores [28]. The highest levels detected were in the range associated with aspirin use in man and only the crustacean body fluid samples examined did not contain SA.
\nAnimal | \nPhylogenetic class | \nSA (μmol/L) | \n
---|---|---|
Burrowing Owl | \nAves | \n9.854 | \n
Ne-Ne | \nAves | \n5.609 | \n
Indian Rhinoceros | \nMammalia | \n4.700 | \n
Pigmy Hippopotamus | \nMammalia | \n2.384 | \n
Agouti | \nMammalia | \n2.116 | \n
Asian Elephant | \nMammalia | \n1.635 | \n
Burmese Python | \nReptilia | \n1.362 | \n
Rabbit | \nMammalia | \n1.129 | \n
Piglet | \nMammalia | \n1.010 | \n
Arabian Onyx | \nMammalia | \n0.777 | \n
Sheep | \nMammalia | \n0.715 | \n
Tiger\na\n\n | \nMammalia | \n0.661 | \n
Brown Trout | \nPisces | \n0.538 | \n
Giraffe | \nMammalia | \n0.507 | \n
Donkey | \nMammalia | \n0.473 | \n
Sacred Ibis | \nAves | \n0.353 | \n
Goat | \nMammalia | \n0.310 | \n
Giant Anteater | \nMammalia | \n0.293 | \n
Collared Peccary | \nReptilia | \n0.237 | \n
African Lion\na\n\n | \nMammalia | \n0.226 | \n
Cow | \nMammalia | \n0.216 | \n
Gelada Baboon | \nMammalia | \n0.210 | \n
Chinese Alligator | \nMammalia | \n0.156 | \n
Domestic Cat | \nMammalia | \n0.144 | \n
Pond Heron | \nAves | \n0.136 | \n
Gorilla | \nMammalia | \n0.125 | \n
Monkey*\n | \nMammalia | \n0.080 | \n
Mouse | \nMammalia | \n0.078 | \n
Rat | \nMammalia | \n0.069 | \n
Domestic Cat**\n | \nMammalia | \n0.058 | \n
Chimpanzee | \nMammalia | \n0.033 | \n
Crab***\n | \nCrustacea | \n<0.005 | \n
Prawn | \nCrustacea | \n<0.005 | \n
Concentration of salicylic acid (SA) in the blood or body fluid of a variety of animals.
Mean concentration in five animals.
Red faced spider monkey.
Fed only meat.
European shore crab.
As some bacteria, notably Mycobacterial, Yersinia and Pseudomonas species, synthesise SA to enhance iron chelation (see Section 5.1) the possibility of a gastrointestinal particularly colonic, bacterial source for SA was assessed in two animal models. Pooled serum from six mice treated with neomycin 100 mg/kg/day for 4 days had a serum SA concentration which was, at 0.309 μmol/L, slightly higher than the level of 0.268 μmol/L measured in six untreated animals. Other measurements were done on serum samples from Sprague-Dawley rats delivered by caesarean section, raised in a sterile environment and fed sterilised food. A group of 8 such germ free animals had a pooled serum SA level which was, at 0.166 μmol/L, ∼2.5× greater than the level of 0.069 μmol/L in serum from a group of control animals [28].
\nA preliminary study followed serum SA and urinary SA + SU over 3 days on a water/milk diet (confirmed salicylate free on analysis) in a subject free of aspirin for at least 2 weeks. Excretion of SA + SU continued at a rate of ∼2.1 μmol/24 h throughout and serum SA did not fall—over the 72 h of the study—below 0.1 μmol/L (20× the limit of detection of the assay) [28].
\nIn six patients who had total colectomy or rectal excision following standard pre-operative bowel preparation low level serum SA (range 0.012–0.085 μmol/L) was detected and urinary SA + SU excretion persisted (median lowest level 0.613 μmol/24 h; range 0.184–7.607) in all subjects for up to 5 days postoperatively, rising only on refeeding [28]. These results also, of course, have some relevance to Section 4.2.
\nBenzoic acid (BA) is a natural constituent of plants, with high levels found in fruits and vegetables. In plants synthesis of SA derives—at least partially—from phenylalanine via cinnamic and benzoic acids. Prior work, using formula diet feeding, also demonstrated that hippuric acid, the main metabolite of BA, may be formed endogenously in man, while a Sprague-Dawley rat radiolabeled experiment showed phenylalanine as the likely precursor [32]. Sodium benzoate as a food preservative also contributes to human intake and very high doses have been used in hepatic encephalopathy. These considerations led us to determine whether addition of BA to a very carefully standardised diet produced any change in serum or urinary salicylates—see Figure 1.
\nA preliminary study, over 4 days in two subjects, suggested that BA, 1 or 2 g/day on days 3 and 4 might be associated with a modest increase in urinary SA + SU excretion. Subsequently a labelled study was undertaken over 3 days in six individuals (4 M, 2F) who received 1 g of uniformly ring-labelled 13C BA with each of their main meals on day 2. They replicated their carefully recorded day 1 diet throughout and had regular blood sampling with complete urine collections. The total SA + SU urinary excretion increased, but not significantly (p = 0.052) and only in the 8–16 h sample after the first dose of BA. While no 13C was detected in samples prior to ingestion of the BA, the 13C isotope was confirmed in the 8–16 h urine sample from all six subjects. Its presence was determined by preliminary GC fractionation before subjecting the relevant fractions to derivatization and GC–MS. The 13C isotope accounted, by selective ion monitoring, for 0.4–10.9% (median 3.4%) in the SA derivative and 6.8–43.1% (median 33.9%) in the SU derivative. In addition considerable amounts of the expected 13C6-labelled hippuric acid were found [28]. Set against the total SA + SU levels the extent of the SU 13C6 labelling found might be considered surprising but could, as well as confirming the in vivo synthesis of SA, point to possible bioregulation of the levels of endogenous serum SA.
\nThe protean actions of aspirin in animals and man are here, in a short review by JRL an GJB, set against what is known of the role of its SA precursor in earlier life forms.
\nThis complex area is here only briefly overviewed in relation to its potential for pointing to possible effects of SA preserved into animals.
\nPara-aminosalicylic acid (PAS), the earliest truly effective anti-tuberculous agent, was long thought an analogue for para-aminobenzoic acid and so an inhibitor of folic acid biosynthesis. That was before the discovery of the mycobacterial siderophore (iron binding molecule) mycobactin, and that SA (also formed, as an extracellular metabolite, by mycobacteria in iron deficient conditions) is its direct precursor. It appears PAS primarily inhibits the conversion of SA into myobactin. Possible secondary roles for SA are the transfer of Fe2+ across the cell membrane, either for direct incorporation into various porphyrins and apoproteins, or for storage of iron within the cytoplasm in bacterioferritin (both roles also potential targets for PAS) [33].
\nThere are many kinds of bacterial siderophores but SA or one of its hydroxylated metabolites (2,3DHBA) are at the core of the aryl- capped molecules found in E. coli (Enterobactin); Yersinia sp. and Klebsiella pneumoniae (Yersinibactin); Pseudomonas sp.(Pyochelin); Vibrio sp. (Vibriobactin/Vulnibactin) and Acinetobacter baumanii (Acinetobactin) [34]. These authors described a probe for the initial aryl acid activation enzymatic step in the synthetic pathways of these “bactins” (via a non-ribosomal peptide synthetase pathway initiated by adenylation) and suggested lack of human homologues makes this a potential drug target—but see Section 5.3.4.
\nIntriguingly investigation into the bioinorganic chemistry of bacterial siderophores has revealed that many have functional capacities other than mere iron homeostasis. Examples include interactions with other metals such as zinc, copper and boron; signalling agents (referred to as “ferrimones”) in the regulation of genes related to iron metabolism; protection—by those with catecholate structures—from oxidative stress and an antibiotic function in sideromycins [35].
\nFinally bacterial growth in the presence of salicylate can be both beneficial and detrimental. On the one hand an intrinsic multiple antibiotic resistance phenotype can be induced and on the other reduced resistance to some antibiotics might result and bacterial virulence factors may be affected [36]. While the in vivo consequences of these observations is speculative the findings highlight, the authors suggest, the ability of salicylate to alter gene expression; they claim that the only life form not yet (then) shown to be affected by salicylate is the Archaea!
\nWhile salicylic acid (initially from plant sources) has been used in therapeutics for millennia detailed knowledge of its role in plants is relatively recent. Although plant phenolics are diverse and ubiquitous they were traditionally assumed to be unimportant secondary metabolites but SA in plants is a critical hormone playing a direct role in the regulation of many aspects of growth and development as well as in thermogenesis and disease resistance [37]. The first clear evidence came, intriguingly (in relation to its antipyretic qualities in animals), from its role in voodoo lily thermogenesis; that appears to be mediated by stimulation of the mitochondrial alternative respiratory pathway [38]. Soon thereafter its role as a defence signalling hormone was documented—though the ability of plants to develop acquired immunity after pathogen infection was first proposed many years earlier. In the acquired immunity—called “systemic acquired resistance” (SAR)—of plants to biotrophic (i.e. threatening living cells) pathogens, the role of SA is pivotal. Careful study has identified two pathways for its synthesis, numerous proteins that regulate its synthesis and metabolism and some signalling components, including a large number of potential targets/receptors, which operate downstream of SA [39]. This is a perplexing field; for example while the non-specialist can readily appreciate methylation of SA to a volatile ester for transport through the phloem (before demethylation at a site where SA levels are low) subsequent steps are complex. As these authors point out it is increasingly evident that SA does not signal immune response by itself but as part of an intricate network of other plant hormones. We would highlight, from the viewpoint of the present review, their suggestion that it is important to differentiate SA “targets” from the subset (whose criteria, they concede, will be difficult to specify) that meet additional conditions to be designated “receptors” [40]. That idea is particularly relevant when later considering the propensity of aspirin to acetylate many animal protein “receptors”—see Section 5.3.4.
\nThe wide range of basal SA levels between and within plant species, and potential for a biphasic/concentration dependent response may explain some conflicting reports on the spectrum of plant processes it influences. Despite these caveats the long list affected by exogenous SA includes resistance to biotic (pathogen-associated) stress and tolerance to many abiotic stresses (drought, chilling, heat, metal, UV radiation, and salinity/osmotic stress) as well as multiple aspects of plant growth and development. These include photosynthesis, senescence, thermogenesis, respiration, glycolysis, the Krebs cycle and the alternative respiratory pathway [40].
\nAlthough the use of willow extracts had been known for centuries the report of its first well documented use—as a cheaper remedy for “the agues” than expensive cinchona bark—focused on its antipyretic properties. Then, particularly in the decades following the isolation of SA as the active principle, evidence steadily accrued for its efficacy as an analgesic and anti-inflammatory in e.g. acute rheumatic fever.
\nFollowing Hoffman’s synthesis of the apparently better tolerated ester in 1897 use of that compound prevailed. ASA was the prototype non-steroidal anti-inflammatory drug (NSAID); it seems that term arose from a need to distinguish it from the undesirable effects of synthetic steroids. As a prodrug for a long recognised active agent its mode of action was naturally linked to the effects of SA.
\nIt was not until the 1960s that work by Vane and Piper led to the proposal of a single mode of action of ASA in the inhibition of prostaglandin synthesis. The resulting paradigm-shifting series of experiments led to the discovery that inhibition of constitutive COX-1 and of COX-2 (predominantly inducible) by serine side-chain acetylation altered levels of prostaglandins and leukotrienes. This revelation came at a time when the potency of ASA as an inhibitor of platelet aggregation in the treatment of vascular disease was coming to the fore. So Vane’s work explained, in a unitary and coherent way, the multiple pharmacological actions of ASA. The ester prevailed—particularly as SA itself had no significant anti-COX-1 effect on platelets.
\nThis emphasis arose from the apparent efficacy, in cancer chemo-protection, of ASA at the low doses (∼70–100 mg/day) used to inhibit platelet aggregation. Irreversible inhibition of COX-1 in the circulating anucleate platelets ensures that thromboxane A2 formation is prevented throughout their lifespan without, at these doses, suppressing the production of prostacyclin (PGI2) which mediates platelet inhibition and vasodilatation. While that is the principle effect required in vascular disease platelet activation also triggers a host of processes leading to leucocyte recruitment into various tissues and subsequent phenotypic changes in stromal cells contributing to atherosclerosis, intestinal inflammation and cancer as well as atherothrombosis [41]. That review also encompasses the non-COX effects of the widespread acetylation of other proteins by ASA—quoting one study which revealed over 12,000 ASA-mediated acetylations in over 3700 proteins!
\nThere is a trend to describe non-COX, indeed increasingly non-platelet, effects of ASA as “non-canonical”. That tag appears to include almost all actions not demonstrably due to COX acetylation with the possible exception of inhibition of COX-2 gene transcription [4].
\nWe should, however, remind ourselves that
It is generally accepted that although SA is a much weaker inhibitor of COX activity in vitro their anti-inflammatory effects in vivo are comparable [3].
ASA has a very short serum half-life compared with SA [2]; its passage (almost certainly total salicylates were determined) through the blood/brain barrier is slow and incomplete [42]. That observation is particularly relevant to the oft forgotten central action of salicylates [43].
ASA’s antipyretic effect was first validated centuries ago using plant extracts; it is mainly due to inhibition of COX-2 in the hypothalamus [44].
There is a clear dose/response relationship between the analgesic effect of ASA up to a dose of 1.2 g [45] compared with the plateau above ∼100 mg/day for the effect on platelets and its efficacy in chemoprevention of colorectal adenomas [46].
The eminent facility for ASA to acetylate proteins has been known for decades and proteomic studies—see above—have shown its very marked extent. While the functional relationship between such activity and its effects are unclear the blockade of glucose6phosphate dehydrogenase (G6PD), affecting the pentose phosphate pathway, and disruption of mitochondrial respiration may explain platelet autophagy [41]. Clearly, as for SA in plants, caution is required in the strict definition of ASA receptors [39, 40].
\nWhile the above caveat applies the blunderbuss masking effect of acetylation is not a consideration. At least 15 SA binding proteins are described to date [39] but some intriguing examples point to effects on proteins with plant and bacterial homologues.
\nHuman glyceraldehyde3-phosphate dehydrogenase (HsGADPH)—has been identified as a SA binding protein—as it is in plants. In addition to its central role in glycolysis GADPH participates in pathological processes, with effects on viral replication and neuronal cell death [47]. Its suppression, by low μM levels of salicylate, in a model of cell death comparable to that induced by reactive oxygen species (ROS) was found. The authors postulate that likely due to suppression of HsGADPH nuclear translocation, mirroring the effect of the anti-Parkinsonian drug Deprenyl.
\nThe same group have also shown [39, 48] that SA targets human high mobility group box 1 (HMGB1), an abundant chromatin associated protein, present in all animal cells; fungi and plants have related proteins. Its diverse effects modulate inflammatory processes. HMGB1’s many activities and receptors likely account for its multiple roles in human disease which include sepsis, arthritis, atherosclerotic plaque formation and cancer. The effect of SA on HMGB1 occurs at concentrations far lower than those required to inhibit COX enzyme activity; an effect on COX2 is on synthesis rather than activity.
\nAn example of a bacterial homologue enzyme, found in mice, is responsible for synthesis of 2,5DHBA—the iron binding moiety of a mammalian siderophore [49]; that enzyme is a homologue of bacterial EntA which catalyses 2,3DHBA production during enterobactin biosynthesis (Section 5.1). 2,5DHBA can, of course, also derive from the metabolism of SA or benzoic acid.
\nOther orthologs of a plant SA receptor—NAD(P)-reductase like proteins—have been characterised in the human neuroblastoma SK-N-SH cell line and mouse brain tissue [50]. Their results may point, the authors claim, to the existence of a thermoregulation system that is evolutionary conserved.
\nThe few direct studies to validate the assertion 5.3.2a above compared salsalate (which yields only SA on absorption) with SA, generally at the higher doses used in rheumatic diseases. Given what we know about the distribution and relative inhibition of COX1 and COX2 it’s not surprising that at comparable doses effects were similar with a predictable lower gastrointestinal toxicity of SA [51]. The authors suggested that, when ASA was originally marketed, commercial forces equated taste and tolerability/toxicity! These prominent rheumatologists concluded that “non-acetylated salicylates should be preferred to ASA in rheumatology”. They clearly supported the German proverb:- “Bitter im Mund, gesund im Korper.”
\nWhile the NSAID categorisation originally served to differentiate the side effects of SA and steroids, very early work had shown a CNS effects specific to salicylates. Later studies—stimulated by discovery of the antipyretic/anti-inflammatory actions of the neuropeptide α-melanocyte stimulating hormone (αMSH)—clearly demonstrated peripheral effects of salicylates introduced into the CNS by injection into the lateral ventricle. These experiments showed that CNS doses which had no effect systemically had a marked effect on the mouse model of inflammation used. The effect was restricted to the salicylates; central injection of an anti-inflammatory dose (when given intra-peritoneally) of indomethacin had no effect: neither did intraventricular dexamethasone or prostaglandin E2 [43].
\nMore recent work on peroxisome proliferator-activated receptors (PPARs) has also shown the importance of central nervous system actions. Peroxisomes are oxidative (H2O2 producing) organelles subserving redox regulation and metabolism of very long chain fatty acids. They are abundant in the CNS, where such fatty acids abound and their increase, when required, is receptor mediated. Studies have compared the anti-inflammatory effect of agonists of PPARα and PPARγ (themselves inactive at the site of inflammation) with the effect of dexamethasone and ASA. Only other agonists and ASA (which itself has generally no direct2 PPAR agonist effect) were found to diminish inflammation when given after the inflammatory insult in contrast to the effect of dexamethasone. The conclusion was that PPARα and PPARγ regulate inflammation through a mechanism similar to salicylates and distinct from that ascribed to steroids [53]. The authors postulated that activating PPARs in the CNS could elicit the release of a salicylate-like compound, an endosalicylate, which may subsequently cause the release of a physiological anti-inflammatory substance such as αMSH.
\nThese results on CNS activity point to steroid/NSAID differentiation which is at least partially dependent on how agents influence the anti-inflammatory and immunomodulatory effect of melanocortins (ACTH and MSH).
\nGiven the ever increasing complexity of SA and ASA effects revealed by basic research it seems blinkered to increasingly restrict focus to platelet/COX effects in the biomedical field.
\nWe reiterate our conclusion that ASA is no mere anti-platelet prototype [54]. That is the case, we aver, for most of the protean pathophysiological effects of ASA and not solely in cancer chemoprevention. The evidence summarised here, particularly our demonstration of the in-vivo synthesis of SA, points to it as a truly endogenous molecule in animals and man. Potential “preserved” receptors which have been described are there, we suggest, not simply to deal with ingested SA or other exogenous precursors.
\nThe place of SA in the biosphere overall is, we think, as pivotal as it appears to be in plants. While a unifying hypothesis to explain its many roles is elusive we suspect they all ultimately relate to the need for evolving life to balance its requirements for oxygen and iron [55]. These authors concluded that the sequestration of iron to restrict its reaction with reactive oxygen species (ROS) is one of our major antioxidant defence mechanisms. They particularly emphasise, in that summary, how such sequestration remains critical to our ongoing resistance to bacterial infection.
\nThe huge increase in energy production arising from enzymatic reduction of oxygen enabled evolution of multicellular animal life. While that was an evolutionary milestone ability to use the resulting reactive oxygen species (ROS) for cell signalling and regulation may have been the first true breakthrough in development of complex life [56]. By then SA was already well established and poised to interact (with ROS) as required. In animals its many effects are unlikely to be less complex than the interactions steadily becoming clarified in plants [39]. Many may depend upon the type of intricate relationships which initiate plant systemic acquired resistance (SAR) with an initial SA induced redox change. Subsequent SA concentration sensitive oligomer/monomer transformation permits nuclear translocation of a cytosolic messenger to activate immune-associated genes [40].\n
\nRe-focus on the importance of the SA moiety of ASA should also lead to further evaluation of SA derivatives which are more active than SA itself in interaction with particular “binding protein/receptors” [47, 48]. At a more basic level we have previously pointed out that, particularly to extend its use in prophylaxis, the risk/benefit profile of ASA may be improved with an SA/ASA combined formulation [54].
\nGiven what we have learned on this investigative journey it is somewhat paradoxical that we embarked upon it driven by desire to capitalise on the hydroxylation of ASA as a biomarker of oxidative “stress” in man—see Section 2.
\nDr. John Robert Paterson (1955–2004), our dear friend who initiated and steered this line of research, always—from schooldays onwards—thought of himself as a chemist first and foremost. Through his long and arduous training in pharmacy, medicinal chemistry, medicine, royal college membership and clinical biochemistry he described himself as a chemist. Most of the work summarised herein, including results published after his death, was either planned by him or arose from discussions during his life. Our prime purpose in undertaking this compilation has been to remain true to his vision. We only pray that there are no glaring chemical errors—the fault is entirely ours if there are.
\nWe are grateful to Hannah Mortlock for the preparation of Figure 1.
\nThe authors declare no conflict of interest.
We wish to thank Dumfries and Galloway Health Board for their support over the many years of these studies, especially their Research and Development and Library services.
\nOur work has been supported financially by the Dumfries and Galloway Health Board’s Salicylic Acid Research Endowment Fund.
\nWe have done our utmost to accurately reflect the findings and conclusions of the many authors quoted in Section 5. Profuse apologies if our reflections on their studies appear at variance with their interpretations.
\nCancer is one of the current main public health problems in the world, accounting for, according to GLOBOCAN, approximately 18.1 million new cases and 9.6 million deaths, worldwide in 2018 [1]. It arises from genetic and environmental interactions that cause the deregulation of signaling pathways involved in fundamental cellular processes. Being a heterogeneous disease with multiple etiologies, cancer shows different pathological evolutions and treatment approaches [2]. Renal Cell Carcinoma (RCC) and Prostate Cancer (PCa) represent the most lethal and common urological cancers, respectively [1].
Kidney cancer represents 403,000 new cases and 175,000 deaths worldwide, with RCC accounting for 90% of these cases [1]. Because of kidney’s anatomic location, these tumors only become symptomatic in the late stages of the disease. Even though about 60% of RCCs are incidentally detected in an early stage because of routine imaging, about 30% are still diagnosed at the symptomatic phase, which is usually associated with worse prognosis [3]. Additionally, most of the patients continue to be diagnosed with locally advanced disease, with about 17% of them presenting distant metastasis at the diagnosis [4]. Apart from these, approximately 40% of patients submitted to surgery with curative intent will also relapse in a 5-year period [5]. Because of its radio and chemo-resistance, targeted therapies are the only agents available to manage metastatic patients, but one fourth of the patients never respond to them, and the ones who do, typically develop resistance in a median of 5–11 months of treatment [6].
On the other hand, with a world estimate of 1.2 million cases and more than 350 thousand deaths in 2018, PCa is the second most frequent cancer in men and the fifth cause of death [1]. Its treatment depends on the grade, stage and age of the patients, being the androgen deprivation therapy (ADT) one of the main therapy options because of its high dependence on the androgen pathway [7]. Despite the initial high response rates, nearly all men that undergo ADT develop resistance within 2 to 3 years, progressing to Castration Resistant PCa (CRPC) [8]. In the last few years new drugs came up as alternatives to these patients, but they present limited time benefits and patients eventually relapse [9].
The late diagnosis, the lack of accurate prognosis and disease follow up biomarkers, as well as the resistance to the existing therapies are some of the major current challenges in both prostate and renal cell carcinoma [10, 11]. Thus, there is an urgent need of more accurate and sensitive biomarkers as well as alternative therapeutic approaches in these tumor models.
Almost 10 years ago, in 2011, the reprogramming of energy metabolism was considered a hallmark of cancer and in the last few years the scientific community has devoted their time to better understand it in order to develop new therapeutic approaches and biomarkers [2]. Oxidoreductases (enzymes that catalyze electrons transfer from one molecule to another) play an important part in these deregulations since they are present in the different pathways involved in cells metabolism, namely in glucose’s metabolism [12].
Glucose, as one of the major “fuels” of any cell, has its metabolism altered in most tumor models [13]. However, because cancer is a heterogeneous disease, this deregulation depends on the type of cells that the tumor arises from, being RCC and PCa a good example of such differences.
RCC is a heterogeneous group of cancers with different genetic and molecular alterations, and histological and clinical characteristics [14]. Clear cell RCC (ccRCC) accounts for about 80% of RCC cases and the most common genetic event involved in its beginning is the copy number deletion, inactivating mutation and/or epigenetic silencing of von Hippel–Lindau (VHL) [3]. Its loss or inactivation leads to an increase of Hypoxia Inducible Factor alpha (HIF-α), triggering a hypoxic response, even in normoxic conditions, from the cell and a consequent induction of its target genes transcription [15]. These genes are involved in several cellular processes including glucose metabolism (GLUT-1 and GLUT-4) and pH regulation (CAIX). Thus, ccRCC is from a very early beginning in a state of constant pseudo hypoxia [16].
This is the most likely cause of the well-known Warburg Effect which is widely documented in ccRCC [17, 18]. The Warburg Effect, or aerobic glycolysis, was firstly described in 1920 by Otto Warburg and describes cancer cells’ preference to metabolize glucose through glycolysis followed by lactate fermentation instead of oxidative phosphorylation, even in the presence of oxygen (Figure 1) [19]. Very common in many tumors, there are several possible explanations to why cancer cells undergo these alterations, even though the energy resulting from it is significantly lower when compared to oxidative phosphorylation. Using aerobic glycolysis, cancer cells are able to obtain ATP in a faster way and this pathway supports better their high biosynthetic needs [18]. Moreover, the consequent acidification of the microenvironment due to the lactate fermentation is of great advantage to cancer cells since it has been shown to boost their invasiveness and metastatic capacity as well as to inhibit immune rejection [20, 21].
RCC’s glucose metabolic switch. In RCC cells, pyruvate is transformed in lactate, with the production of ATP instead of undergoing Krebs cycle and oxidative phosphorylation (Warburg effect). Created by BioRender.com.
In ccRCC, besides VHL loss, HIF- α can also be stabilized by mechanisms like RAS activation or accumulation of Krebs cycle substrates [22]. Moreover, this effect can also be driven by the interruption of the Krebs Cycle and mutations in genes that encode enzymes like Fumarate Hydratase or Succinate Dehydrogenase, increased levels of reactive oxygen species and activation of pathways such as NRF2/KEAP1 and PI3K/mTOR [18].
In addition to thar, the deregulation of the expression of several enzymes involved in the glucose metabolic pathways has already been reported in ccRCC, including several oxidoreductases, such as glyceraldehyde-3-phosphate dehydrogenase (G3PD), lactate dehydrogenase (LDHA) which belong to the glycolysis pathway; pyruvate dehydrogenase (PD) and isocitrate dehydrogenase (IDH) involved in the Krebs Cycle and succinate dehydrogenase (SDH) which is part of the oxidative phosphorylation pathway [16, 23, 24, 25, 26].
Due to its organ’s function, prostatic tissue shows a unique metabolic activity under normal conditions, which will reflect in the disruptions presented by its cancer cells. One of the key functions of the prostate gland is to produce large amounts of citrate that is secreted as part of the seminal liquid [27]. Thus, normal prostate epithelial cells undergo a very inefficient energy metabolism.
In most organs, glucose is metabolized through glycolysis in pyruvate, which is decarboxylated in the mitochondria to generate Acetyl-CoA. This metabolite reacts with oxalocetate to generate citrate which is oxidized and undergoes the Krebs Cycle where a large amount of NADH is produced (that will be used in oxidative phosphorylation to produce ATP), as well as precursors of several amino acids [28]. In normal prostate epithelial cells, there is an impairment of the mitochondrial aconitase, responsible for citrate oxidization, granting this metabolite accumulation, which is needed in the seminal liquid composition [27]. Aconitase’s inhibition is triggered by an accumulation of zinc in these cells due to the overexpression of the zinc-regulated transporter/iron-regulated transporter-like protein 1 (ZIP1) [29]. Thus, in these cells, citrate is the final product of glucose metabolism and oxaloacetic acid (which normally is regenerated in the Krebs cycle) is produced through aspartate imported from the plasma through a specific carrier [30]. Because of Krebs cycle inhibition, and consequent oxidative phosphorylation impairment, these cells show a higher glycolytic rate [28].
Prostate cancer cells, however, have increased energy demands. Franklin and Costello have concluded that an early event in PCa carcinogenesis is the completion of the Krebs cycle and subsequent ability to produce much more ATP [31]. In fact, PCa cells show dramatically reduced levels of zinc, and consequent reactivation of m-aconitase and of Krebs cycle [32]. Interestingly, zinc has also been shown to induce apoptosis and inhibit invasion and angiogenesis in PCa cells [33, 34].
Nevertheless, it is important to take into consideration that cells need to readjust their bioenergetics and metabolism according to their energetic needs, during cancer progression. Thus, in its metastatic stage, PCa has been shown to switch to Warburg Effect [35]. The exact mechanisms behind this switch are not yet fully understood, but the microenvironment in the metastatic sites seems to play a key role, whether through the neighboring adipocytes or through the immune system. These seem to be able to increase HIF1α’s production inducing aerobic glycolysis and blocking oxidative phosphorylation (Figure 2) [36, 37].
PCa’s glucose metabolic switch. Normal prostate epithelial cells have the Krebs cycle interrupted because of their need to secrete citrate as part of seminal fluid. In prostate cancer, Krebs cycle is resumed because of the increased demand for energy. Warburg effect is only observed in the more advanced stages of the tumor. Created by BioRender.com.
Several oxidoreductases involved in the glucose metabolic pathways have already been studied in PCa and reported as deregulated, such as glyceraldehyde-3-phosphate dehydrogenase (G3PD) and lactate dehydrogenase (LDHA) which belong to the glycolysis pathway and pyruvate dehydrogenase (PD) and isocitrate dehydrogenase (IDH) involved in the Krebs Cycle [38, 39, 40, 41].
The deregulation of the oxidoreductases as well as other enzymes involved in the glucose metabolism pathways is necessary for its reprogramming. This deregulation has already been connected with microRNAs (miRNAs), both in RCC and in PCa [18, 42].
miRNAs are short non-coding RNAs (~19 to 25 nucleotides) which regulate gene expression at a post-transcriptional level. Through binding to the 3′ untranslated region (3’ UTR) of mRNAs, miRNAs induce their degradation or translation repression [43]. These molecules are important modulators of cellular behavior being involved in different biological processes such as cell development, differentiation, apoptosis, proliferation, and metabolism. This is due to their dynamic expression since each miRNA regulates up to 100 different mRNAs and more than 10,000 mRNAs are regulated by miRNAs [44].
There are different characteristics that make miRNAs good biomarkers’ candidates. Firstly, miRNAs have different expression patterns in normal cells when compared with tumoral ones, and even among different subtypes or in different stages of the disease, which shows their potential as biomarkers’ candidates [45]. Secondly, there has been cumulating evidence regarding the fact that miRNAs are secreted into several body fluids, such as serum, plasma, saliva or urine [46]. Finally, miRNAs circulate in these fluids incorporated into protein complexes or extracellular vesicles, which protect them from RNAse degradation and make them resistant to extreme conditions like temperature or pH differences [47].
In fact, in previous studies circulating miRNAs profiles have already been associated with histology, staging and clinical endpoints, including patients’ survival and therapy response both in ccRCC and in PCa [48, 49, 50].
Thus, the study of miRNAs whose targets are involved in the glucose metabolism in tumor models such as RCC and PCa is highly important, not only because it can help to better understand the differences in metabolic deregulations of the different tumors, but also because this knowledge can be applied in designing new-targeted therapies and biomarkers.
This chapter is focused on the three main glycolytic pathways: glycolysis, Krebs cycle and Lactate Fermentation. Since oxidoreductases are present in these three pathways, we chose this type of enzymes to select miRNAs that directly regulate them (Table 1).
Following, we used miRTarBase (version 8.0), the largest known online database of validated miRNA:mRNA target interactions, to select the miRNAs that directly target these enzymes [51]. Only studies featuring hsa-miRNAs and functional miRNA Target Interaction (MTI) evidence were considered. The selected miRNAs and the respective validated targets are displayed in Figure 3.
miRNAs that directly regulate the oxidoreductases involved in the main pathways of glucose catabolism. Created by BioRender.com.
A systematic search in Pubmed was then conducted regarding the existing evidence for each miRNA in both ccRCC and in PCa, in order to get a deeper knowledge of these miRNAs expression in these tumor models. To do so, we combined each miRNA with the following keywords: “renal cell carcinoma”, “RCC”, “Kidney Cancer”; “Prostate Cancer”. The obtained scientific papers were manually curated to determine the association between the miRNA and either RCC or PCa. The criteria of exclusion were the following: 1) scientific papers that do not report results from human samples; 2) scientific papers that do not directly correlate the miRNA with the disease. From the 56 papers initially found, 23 were excluded. For each selected paper, we extracted information regarding the deregulation of the miRNA’s expression in each tumor model (upregulated ↑/downregulated ↓) and gathered it in the following tables, according to the metabolic processes involved.
Glycolysis is the pathway responsible for converting glucose in pyruvate and it is constituted by a series of enzymatic reactions. Its sixth step is catalyzed by an oxidoreductase - Glyceraldehyde_3-phosphate_dehydrogenase (GAPDH) – responsible for transforming glyceraldehyde 3-phosphate in D-glycerate 1,3-biphosphate. According to miRTarBase (version 8.0), GAPDH is directly targeted by miR-29c-3p and miR-644a [51]. The studies regarding these miRNAs in both RCC and PCa are scarce, and miR-644a’s expression is still not described in RCC nor miR-29c-3p’s expression is described in PCa (Tables 2 and 3).
Glycolysis | Lactate fermentation | Krebs cycle |
---|---|---|
GAPDH | LDHA | PDH |
IDH | ||
KGDH | ||
SDH | ||
MDH |
Oxidoreductases in glycolysis, lactate fermentation and Krebs cycle.
Enzyme | miRNA | Sample type | Outcome | References |
---|---|---|---|---|
GAPDH | miR-29c-3p | Tissues and Cell lines | ↓ | [52] |
Deregulation of the miRNAs that directly target the glycolysis’ oxidoreductases in RCC.
Enzyme | miRNA | Sample type | Outcome | References |
---|---|---|---|---|
GAPDH | miR-644a | Tissues | ↓ | [53] |
Deregulation of the miRNAs that directly target the glycolysis’ oxidoreductases in PCa.
In both tumor models, the miRNAs targeting GAPDH are downregulated, which may partly explain the upregulation of GADPH already observed in PCa [52, 53]. There is, in fact, an increase of glucose consumption in cancer due to the bigger energetic needs of tumoral cells. Since glycolysis is the basis of glucose catabolism, either by following Krebs Cycle or Lactate Fermentation, the upregulation of the expression of this pathway’s enzymes will help ensure cancer cells’ catabolic demands.
Lactate fermentation is the metabolic process in which the pyruvate resulting from glycolysis is transformed in lactate with ATP production. This reaction is catalyzed by an oxidoreductase – Lactate Dehydrogenase (LDHA), whose mRNA, according to miRTarBase (version 8.0), is directly targeted by miR-34a-5p, miR-23a-3p, miR-24-3p, miR-210-3p, miR-374a-5p and miR-200b-3p [51]. To the best of our knowledge, there are still no studies regarding miR-24-3p and miR-374a-5p’s expression in RCC as well as miR-374a-5p’s expression in PCa. The studies regarding the other miRNA’s expression in RCC are summarized in Table 4 and the ones regarding miRNA’s expression in PCa are summarized in Table 5.
Enzyme | miRNA | Sample type | Outcome | References |
---|---|---|---|---|
LDHA | miR-34a-5p | Cell lines | ↑ | [54] |
Tissues and cell lines | ↑ | [55] | ||
Tissues | ↓ | [56] | ||
miR-23a-3p | Cell lines | ↓ | [57] | |
Tissues and cell lines | ↑ | [58] | ||
miR-210-3p | Tissues | ↑ | [59] | |
Cell lines | ↓ | [60] | ||
Cell lines | ↓ | [61] | ||
Tissues and urine | ⇅ | [62] | ||
Tissues | ↑ | [63] | ||
Tissues and urine | ⇅ | [64] | ||
Tissues | ↑ | [65] | ||
Cell lines and plasma | ↑ | [66] | ||
miR-200b-3p | Cell lines | ↓ | [67] |
Deregulation of the miRNAs that directly target the lactate Fermentation’s oxidoreductases in RCC.
Enzyme | miRNA | Sample type | Outcome | References |
---|---|---|---|---|
LDHA | miR-34a-5p | Cell lines (resistant vs. hormonal sensitive) | ↓ | [68] |
Urinary exosomes and tissues | ↓ | [69] | ||
Cell lines | ↓ | [70] | ||
miR-23a-3p | Tissues | ↑ | [71] | |
miR-24-3p | Urine | ↓ | [72] | |
Urine | ↓ | [73] | ||
Tissues and cell lines | ↓ | [74] | ||
miR-210-3p | Tissues | ↑ | [75] | |
Tissues | ↑ | [76] | ||
miR-200b-3p | Tissues | ↑ | [77] | |
Cell lines | ↓ | [78] | ||
Metastatic tissues | ↓ | [79] | ||
Chemo-resistant cells | ↑ | [80] |
Deregulation of the miRNAs that directly target the lactate fermentation’s oxidoreductases in PCa.
In RCC, the available studies for the selected miRNAs are controversial. This may be result of lack of standardized procedures but also of the different types of samples analyzed. Moreover, it is interesting to look at the studies of miR-210-3p’s expression. This miRNA was significantly increased in ccRCC patients at the time of surgery, when compared to healthy donors, but significantly decreased in follow-up disease-free ccRCC patients of the same cohort [62, 64]. These studies show, not only this miRNA potential as follow-up biomarker but are also an example of miRNAs dynamic expression. In PCa, one can notice that hormonal resistant and metastatic PCa show a decrease in miR-34a-5p and miR-200b-3p, which may traduce in an increase of LDHA and the switch to Warburg Effect which is only observed in these stages of PCa [68, 79].
Krebs Cycle, also known as the tricarboxylic acid cycle, follows glycolysis in the glucose catabolism when oxygen is present. It is preceded by the transformation of pyruvate in acetyl-coA, which will enter the cycle – a series of reactions that provide precursors of amino acids as well as the reducing agent NADH which will be used in the oxidative phosphorylation pathway and lead to ATP production.
Pyruvate oxidation in acetyl-coA is catalyzed by an oxidoreductase – Pyruvate dehydrogenase (PDH), whose mRNA is, according to miRTarBase (version 8.0) directly targeted by miR-96-3p [51]. However, there are still no studies regarding this miRNA in both RCC and in PCa.
In the series of reactions of Krebs Cycle, there are 4 reactions catalyzed by 4 oxidoreductases – Isocitrate dehydrogenase (IDH), α-ketoglutarate dehydrogenase (KDGH), Succinate dehydrogenase (SDH) and Malate dehydrogenase (MDH). According to miRTarBase (version 8.0), miRNAs directly targeting KDGH and MDH were not yet identified. Moreover, SDH is directly targeted by miR-31-3p, which, to the best of our knowledge, has not yet been studied in RCC and in PCa [51].
IDH is directly targeted by miR-30c-5p. There are few studies regarding this miRNA both in RCC (Table 6) and in PCa (Table 7).
Deregulation of the miRNAs that directly target the Krebs cycle’s oxidoreductases in RCC.
Deregulation of the miRNAs that directly target the Krebs Cycle’s oxidoreductases in PCa.
In these studies, the expression of miR-30c-5p in RCC is downregulated which would suggest an upregulation of IDH’s mRNA expression. However, this protein was shown to be downregulated in this tumor model [85]. In fact, a single mRNA can be regulate by several miRNAs, making the miRNA:mRNA expression not always inversely correlated. Nevertheless, the fact that miR-30-c-5p was downregulated in urinary exosomes shows its potential as a biomarker in a liquid biopsy approach [81].
In PCa the results regarding this miRNA are scarce and controversial, showing the need of more studies to clarify its expression levels.
miRNAs potential in the oncology field has been widely recognized and there has been an increase of studies regarding their deregulation in cancer in the last few years. However, there are many genes whose mRNA have not been identified as direct targets of any miRNA. In this book chapter, both KGDH and MDH, key enzymes in the Krebs Cycle, have not been directly associated with any miRNAs. Moreover, there are several miRNAs that directly target the mRNA of key enzymes of glucose catabolism but have not yet been studied in RCC (miR-644a, miR-24-3p, miR-374a-5p, miR-96-3p and miR-31-3p) and in PCa (miR-29c-3p, miR-374a-5p, miR96-3p, miR-31-3p). Additionally, some miRNAs present controversial results which shall be subject of more studies to confirm their deregulation. Nevertheless, two miRNAs have been identified as downregulated (miR-29c-3p and miR-200b-2p) in RCC and three miRNAs have been identified as downregulated (miR-644a, miR-34a-5p and miR-24-3p) and two as upregulated (miR-23a-3p and miR-210-3p) in PCa. Their potential as biomarkers of both RCC and PCa could be increased if combined as a profile, which could pose as an advance to establish a successful liquid biopsy approach.
Because of their influence in their target genes’ expression, the reestablishment of miRNAs’ levels may have a great impact in the regulation of glucose metabolism. Restoring the levels of the downregulated miRNAs in both RCC and PCa could benefit the current cancer therapies and one possible way to do so is through a nanomedicine approach. Nanoparticles (NPs) are small organized structures with sizes between in size 1 and 100 nm that show very specific chemical and physical properties due to their size and composition [86]. Even though the existing research is scarce, NPs can improve the specificity of miRNAs delivery to target cells (thus reducing side effects) and allow for controlled miRNA release [87]. They also can protect them from degradation and prevent their clearance by the reticuloendothelial system. Moreover, they avoid unfavorable immune cell stimulation [87]. NPs highly depend on their capping which acts prevents their agglomeration and stops uncontrolled growth. The choice of capping will highly influence NPs properties. To effectively deliver the miRNAs selected in this chapter, a glucose capping could be an interesting choice. As stated above, both in RCC and PCa, tumoral cells show an increased glucose consumption when compared with their counterpart normal cells. Thus, glucose as NP’s capping could favor the selective delivery of miRNAs and would likely not be recognized as antagonist by the immune system.
The deregulation of glucose metabolism as a great influence in the pathophysiology of cancer, with the oxidoreductases involved in its pathways posing as both an opportunity to better comprehend the disease and finding not only strategies of detecting and monitoring it but also new therapeutic strategies. miRNAs could be part of these strategies since they influence the expression of these enzymes. Both in RCC and PCa, there are studies regarding miRNAs that target these oxidoreductases, showing their impact in patients’ prognosis. In the future, more studies are needed, regarding the identification of more miRNAs that target for example KGDH and MDH and their validation in RCC and PCa. Moreover, exploring the potential of glucose capped NPs carrying these miRNAs could help establish new therapeutic strategies that would benefit RCC and PCa management.
We would like to thank Liga Portuguesa Contra o Cancro – Núcleo Regional do Norte – LPCC-NRN (Portuguese League against Cancer). M.M. is a recipient of a research scholarship awarded by LPCC-NRN (Portuguese League against Cancer—Northern Branch). F.D. is a recipient of a research fellowship from the project NORTE-01-0247-FEDER-033399, supported by Norte Portugal regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through European Regional Development Fund (ERDF).
The authors declare no conflict of interest.
You have been successfully unsubscribed.
",metaTitle:"Unsubscribe Successful",metaDescription:"You have been successfully unsubscribed.",metaKeywords:null,canonicalURL:"/page/unsubscribe-successful",contentRaw:'[{"type":"htmlEditorComponent","content":""}]'},components:[{type:"htmlEditorComponent",content:""}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"105746",title:"Dr.",name:"A.W.M.M.",middleName:null,surname:"Koopman-van Gemert",slug:"a.w.m.m.-koopman-van-gemert",fullName:"A.W.M.M. Koopman-van Gemert",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/105746/images/5803_n.jpg",biography:"Dr. Anna Wilhelmina Margaretha Maria Koopman-van Gemert MD, PhD, became anaesthesiologist-intensivist from the Radboud University Nijmegen (the Netherlands) in 1987. She worked for a couple of years also as a blood bank director in Nijmegen and introduced in the Netherlands the Cell Saver and blood transfusion alternatives. She performed research in perioperative autotransfusion and obtained the degree of PhD in 1993 publishing Peri-operative autotransfusion by means of a blood cell separator.\nBlood transfusion had her special interest being the president of the Haemovigilance Chamber TRIP and performing several tasks in local and national blood bank and anticoagulant-blood transfusion guidelines committees. Currently, she is working as an associate professor and up till recently was the dean at the Albert Schweitzer Hospital Dordrecht. She performed (inter)national tasks as vice-president of the Concilium Anaesthesia and related committees. \nShe performed research in several fields, with over 100 publications in (inter)national journals and numerous papers on scientific conferences. \nShe received several awards and is a member of Honour of the Dutch Society of Anaesthesia.",institutionString:null,institution:{name:"Albert Schweitzer Hospital",country:{name:"Gabon"}}},{id:"83089",title:"Prof.",name:"Aaron",middleName:null,surname:"Ojule",slug:"aaron-ojule",fullName:"Aaron Ojule",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Port Harcourt",country:{name:"Nigeria"}}},{id:"295748",title:"Mr.",name:"Abayomi",middleName:null,surname:"Modupe",slug:"abayomi-modupe",fullName:"Abayomi Modupe",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/no_image.jpg",biography:null,institutionString:null,institution:{name:"Landmark University",country:{name:"Nigeria"}}},{id:"94191",title:"Prof.",name:"Abbas",middleName:null,surname:"Moustafa",slug:"abbas-moustafa",fullName:"Abbas Moustafa",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/94191/images/96_n.jpg",biography:"Prof. Moustafa got his doctoral degree in earthquake engineering and structural safety from Indian Institute of Science in 2002. He is currently an associate professor at Department of Civil Engineering, Minia University, Egypt and the chairman of Department of Civil Engineering, High Institute of Engineering and Technology, Giza, Egypt. He is also a consultant engineer and head of structural group at Hamza Associates, Giza, Egypt. Dr. Moustafa was a senior research associate at Vanderbilt University and a JSPS fellow at Kyoto and Nagasaki Universities. He has more than 40 research papers published in international journals and conferences. He acts as an editorial board member and a reviewer for several regional and international journals. His research interest includes earthquake engineering, seismic design, nonlinear dynamics, random vibration, structural reliability, structural health monitoring and uncertainty modeling.",institutionString:null,institution:{name:"Minia University",country:{name:"Egypt"}}},{id:"84562",title:"Dr.",name:"Abbyssinia",middleName:null,surname:"Mushunje",slug:"abbyssinia-mushunje",fullName:"Abbyssinia Mushunje",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"University of Fort Hare",country:{name:"South Africa"}}},{id:"202206",title:"Associate Prof.",name:"Abd Elmoniem",middleName:"Ahmed",surname:"Elzain",slug:"abd-elmoniem-elzain",fullName:"Abd Elmoniem Elzain",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Kassala University",country:{name:"Sudan"}}},{id:"98127",title:"Dr.",name:"Abdallah",middleName:null,surname:"Handoura",slug:"abdallah-handoura",fullName:"Abdallah Handoura",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"École Supérieure des Télécommunications",country:{name:"Morocco"}}},{id:"91404",title:"Prof.",name:"Abdecharif",middleName:null,surname:"Boumaza",slug:"abdecharif-boumaza",fullName:"Abdecharif Boumaza",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Abbès Laghrour University of Khenchela",country:{name:"Algeria"}}},{id:"105795",title:"Prof.",name:"Abdel Ghani",middleName:null,surname:"Aissaoui",slug:"abdel-ghani-aissaoui",fullName:"Abdel Ghani Aissaoui",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/105795/images/system/105795.jpeg",biography:"Abdel Ghani AISSAOUI is a Full Professor of electrical engineering at University of Bechar (ALGERIA). He was born in 1969 in Naama, Algeria. He received his BS degree in 1993, the MS degree in 1997, the PhD degree in 2007 from the Electrical Engineering Institute of Djilali Liabes University of Sidi Bel Abbes (ALGERIA). He is an active member of IRECOM (Interaction Réseaux Electriques - COnvertisseurs Machines) Laboratory and IEEE senior member. He is an editor member for many international journals (IJET, RSE, MER, IJECE, etc.), he serves as a reviewer in international journals (IJAC, ECPS, COMPEL, etc.). He serves as member in technical committee (TPC) and reviewer in international conferences (CHUSER 2011, SHUSER 2012, PECON 2012, SAI 2013, SCSE2013, SDM2014, SEB2014, PEMC2014, PEAM2014, SEB (2014, 2015), ICRERA (2015, 2016, 2017, 2018,-2019), etc.). His current research interest includes power electronics, control of electrical machines, artificial intelligence and Renewable energies.",institutionString:"University of Béchar",institution:{name:"University of Béchar",country:{name:"Algeria"}}},{id:"99749",title:"Dr.",name:"Abdel Hafid",middleName:null,surname:"Essadki",slug:"abdel-hafid-essadki",fullName:"Abdel Hafid Essadki",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"École Nationale Supérieure de Technologie",country:{name:"Algeria"}}},{id:"101208",title:"Prof.",name:"Abdel Karim",middleName:"Mohamad",surname:"El Hemaly",slug:"abdel-karim-el-hemaly",fullName:"Abdel Karim El Hemaly",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/101208/images/733_n.jpg",biography:"OBGYN.net Editorial Advisor Urogynecology.\nAbdel Karim M. A. El-Hemaly, MRCOG, FRCS � Egypt.\n \nAbdel Karim M. A. El-Hemaly\nProfessor OB/GYN & Urogynecology\nFaculty of medicine, Al-Azhar University \nPersonal Information: \nMarried with two children\nWife: Professor Laila A. Moussa MD.\nSons: Mohamad A. M. El-Hemaly Jr. MD. Died March 25-2007\nMostafa A. M. El-Hemaly, Computer Scientist working at Microsoft Seatle, USA. \nQualifications: \n1.\tM.B.-Bch Cairo Univ. June 1963. \n2.\tDiploma Ob./Gyn. Cairo Univ. April 1966. \n3.\tDiploma Surgery Cairo Univ. Oct. 1966. \n4.\tMRCOG London Feb. 1975. \n5.\tF.R.C.S. Glasgow June 1976. \n6.\tPopulation Study Johns Hopkins 1981. \n7.\tGyn. Oncology Johns Hopkins 1983. \n8.\tAdvanced Laparoscopic Surgery, with Prof. Paulson, Alexandria, Virginia USA 1993. \nSocieties & Associations: \n1.\t Member of the Royal College of Ob./Gyn. London. \n2.\tFellow of the Royal College of Surgeons Glasgow UK. \n3.\tMember of the advisory board on urogyn. FIGO. \n4.\tMember of the New York Academy of Sciences. \n5.\tMember of the American Association for the Advancement of Science. \n6.\tFeatured in �Who is Who in the World� from the 16th edition to the 20th edition. \n7.\tFeatured in �Who is Who in Science and Engineering� in the 7th edition. \n8.\tMember of the Egyptian Fertility & Sterility Society. \n9.\tMember of the Egyptian Society of Ob./Gyn. \n10.\tMember of the Egyptian Society of Urogyn. \n\nScientific Publications & Communications:\n1- Abdel Karim M. El Hemaly*, Ibrahim M. Kandil, Asim Kurjak, Ahmad G. Serour, Laila A. S. Mousa, Amr M. Zaied, Khalid Z. El Sheikha. \nImaging the Internal Urethral Sphincter and the Vagina in Normal Women and Women Suffering from Stress Urinary Incontinence and Vaginal Prolapse. Gynaecologia Et Perinatologia, Vol18, No 4; 169-286 October-December 2009.\n2- Abdel Karim M. El Hemaly*, Laila A. S. Mousa Ibrahim M. Kandil, Fatma S. El Sokkary, Ahmad G. Serour, Hossam Hussein.\nFecal Incontinence, A Novel Concept: The Role of the internal Anal sphincter (IAS) in defecation and fecal incontinence. Gynaecologia Et Perinatologia, Vol19, No 2; 79-85 April -June 2010.\n3- Abdel Karim M. El Hemaly*, Laila A. S. Mousa Ibrahim M. Kandil, Fatma S. El Sokkary, Ahmad G. Serour, Hossam Hussein.\nSurgical Treatment of Stress Urinary Incontinence, Fecal Incontinence and Vaginal Prolapse By A Novel Operation \n"Urethro-Ano-Vaginoplasty"\n Gynaecologia Et Perinatologia, Vol19, No 3; 129-188 July-September 2010.\n4- Abdel Karim M. El Hemaly*, Ibrahim M. Kandil, Laila A. S. Mousa and Mohamad A.K.M.El Hemaly.\nUrethro-vaginoplasty, an innovated operation for the treatment of: Stress Urinary Incontinence (SUI), Detursor Overactivity (DO), Mixed Urinary Incontinence and Anterior Vaginal Wall Descent. \nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/ urethro-vaginoplasty_01\n\n5- Abdel Karim M. El Hemaly, Ibrahim M Kandil, Mohamed M. Radwan.\n Urethro-raphy a new technique for surgical management of Stress Urinary Incontinence.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/\nnew-tech-urethro\n\n6- Abdel Karim M. El Hemaly, Ibrahim M Kandil, Mohamad A. Rizk, Nabil Abdel Maksoud H., Mohamad M. Radwan, Khalid Z. El Shieka, Mohamad A. K. M. El Hemaly, and Ahmad T. El Saban.\nUrethro-raphy The New Operation for the treatment of stress urinary incontinence, SUI, detrusor instability, DI, and mixed-type of urinary incontinence; short and long term results. \nhttp://www.obgyn.net/urogyn/urogyn.asp?page=urogyn/articles/\nurethroraphy-09280\n\n7-Abdel Karim M. El Hemaly, Ibrahim M Kandil, and Bahaa E. El Mohamady. Menopause, and Voiding troubles. \nhttp://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly03/el-hemaly03-ss\n\n8-El Hemaly AKMA, Mousa L.A. Micturition and Urinary\tContinence. Int J Gynecol Obstet 1996; 42: 291-2. \n\n9-Abdel Karim M. El Hemaly.\n Urinary incontinence in gynecology, a review article.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/abs-urinary_incotinence_gyn_ehemaly \n\n10-El Hemaly AKMA. Nocturnal Enuresis: Pathogenesis and Treatment. \nInt Urogynecol J Pelvic Floor Dysfunct 1998;9: 129-31.\n \n11-El Hemaly AKMA, Mousa L.A.E. Stress Urinary Incontinence, a New Concept. Eur J Obstet Gynecol Reprod Biol 1996; 68: 129-35. \n\n12- El Hemaly AKMA, Kandil I. M. Stress Urinary Incontinence SUI facts and fiction. Is SUI a puzzle?! http://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly/el-hemaly-ss\n\n13-Abdel Karim El Hemaly, Nabil Abdel Maksoud, Laila A. Mousa, Ibrahim M. Kandil, Asem Anwar, M.A.K El Hemaly and Bahaa E. El Mohamady. \nEvidence based Facts on the Pathogenesis and Management of SUI. http://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly02/el-hemaly02-ss\n\n14- Abdel Karim M. El Hemaly*, Ibrahim M. Kandil, Mohamad A. Rizk and Mohamad A.K.M.El Hemaly.\n Urethro-plasty, a Novel Operation based on a New Concept, for the Treatment of Stress Urinary Incontinence, S.U.I., Detrusor Instability, D.I., and Mixed-type of Urinary Incontinence.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/urethro-plasty_01\n\n15-Ibrahim M. Kandil, Abdel Karim M. El Hemaly, Mohamad M. Radwan: Ultrasonic Assessment of the Internal Urethral Sphincter in Stress Urinary Incontinence. The Internet Journal of Gynecology and Obstetrics. 2003. Volume 2 Number 1. \n\n\n16-Abdel Karim M. El Hemaly. Nocturnal Enureses: A Novel Concept on its pathogenesis and Treatment.\nhttp://www.obgyn.net/urogynecolgy/?page=articles/nocturnal_enuresis\n\n17- Abdel Karim M. El Hemaly. Nocturnal Enureses: An Update on the pathogenesis and Treatment.\nhttp://www.obgyn.net/urogynecology/?page=/ENHLIDH/PUBD/FEATURES/\nPresentations/ Nocturnal_Enuresis/nocturnal_enuresis\n\n18-Maternal Mortality in Egypt, a cry for help and attention. The Second International Conference of the African Society of Organization & Gestosis, 1998, 3rd Annual International Conference of Ob/Gyn Department � Sohag Faculty of Medicine University. Feb. 11-13. Luxor, Egypt. \n19-Postmenopausal Osteprosis. The 2nd annual conference of Health Insurance Organization on Family Planning and its role in primary health care. Zagaziz, Egypt, February 26-27, 1997, Center of Complementary Services for Maternity and childhood care. \n20-Laparoscopic Assisted vaginal hysterectomy. 10th International Annual Congress Modern Trends in Reproductive Techniques 23-24 March 1995. Alexandria, Egypt. \n21-Immunological Studies in Pre-eclamptic Toxaemia. Proceedings of 10th Annual Ain Shams Medical Congress. Cairo, Egypt, March 6-10, 1987. \n22-Socio-demographic factorse affecting acceptability of the long-acting contraceptive injections in a rural Egyptian community. Journal of Biosocial Science 29:305, 1987. \n23-Plasma fibronectin levels hypertension during pregnancy. The Journal of the Egypt. Soc. of Ob./Gyn. 13:1, 17-21, Jan. 1987. \n24-Effect of smoking on pregnancy. Journal of Egypt. Soc. of Ob./Gyn. 12:3, 111-121, Sept 1986. \n25-Socio-demographic aspects of nausea and vomiting in early pregnancy. Journal of the Egypt. Soc. of Ob./Gyn. 12:3, 35-42, Sept. 1986. \n26-Effect of intrapartum oxygen inhalation on maternofetal blood gases and pH. Journal of the Egypt. Soc. of Ob./Gyn. 12:3, 57-64, Sept. 1986. \n27-The effect of severe pre-eclampsia on serum transaminases. The Egypt. J. Med. Sci. 7(2): 479-485, 1986. \n28-A study of placental immunoreceptors in pre-eclampsia. The Egypt. J. Med. Sci. 7(2): 211-216, 1986. \n29-Serum human placental lactogen (hpl) in normal, toxaemic and diabetic pregnant women, during pregnancy and its relation to the outcome of pregnancy. Journal of the Egypt. Soc. of Ob./Gyn. 12:2, 11-23, May 1986. \n30-Pregnancy specific B1 Glycoprotein and free estriol in the serum of normal, toxaemic and diabetic pregnant women during pregnancy and after delivery. Journal of the Egypt. Soc. of Ob./Gyn. 12:1, 63-70, Jan. 1986. Also was accepted and presented at Xith World Congress of Gynecology and Obstetrics, Berlin (West), September 15-20, 1985. \n31-Pregnancy and labor in women over the age of forty years. Accepted and presented at Al-Azhar International Medical Conference, Cairo 28-31 Dec. 1985. \n32-Effect of Copper T intra-uterine device on cervico-vaginal flora. Int. J. Gynaecol. Obstet. 23:2, 153-156, April 1985. \n33-Factors affecting the occurrence of post-Caesarean section febrile morbidity. Population Sciences, 6, 139-149, 1985. \n34-Pre-eclamptic toxaemia and its relation to H.L.A. system. Population Sciences, 6, 131-139, 1985. \n35-The menstrual pattern and occurrence of pregnancy one year after discontinuation of Depo-medroxy progesterone acetate as a postpartum contraceptive. Population Sciences, 6, 105-111, 1985. \n36-The menstrual pattern and side effects of Depo-medroxy progesterone acetate as postpartum contraceptive. Population Sciences, 6, 97-105, 1985. \n37-Actinomyces in the vaginas of women with and without intrauterine contraceptive devices. Population Sciences, 6, 77-85, 1985. \n38-Comparative efficacy of ibuprofen and etamsylate in the treatment of I.U.D. menorrhagia. Population Sciences, 6, 63-77, 1985. \n39-Changes in cervical mucus copper and zinc in women using I.U.D.�s. Population Sciences, 6, 35-41, 1985. \n40-Histochemical study of the endometrium of infertile women. Egypt. J. Histol. 8(1) 63-66, 1985. \n41-Genital flora in pre- and post-menopausal women. Egypt. J. Med. Sci. 4(2), 165-172, 1983. \n42-Evaluation of the vaginal rugae and thickness in 8 different groups. Journal of the Egypt. Soc. of Ob./Gyn. 9:2, 101-114, May 1983. \n43-The effect of menopausal status and conjugated oestrogen therapy on serum cholesterol, triglycerides and electrophoretic lipoprotein patterns. Al-Azhar Medical Journal, 12:2, 113-119, April 1983. \n44-Laparoscopic ventrosuspension: A New Technique. Int. J. Gynaecol. Obstet., 20, 129-31, 1982. \n45-The laparoscope: A useful diagnostic tool in general surgery. Al-Azhar Medical Journal, 11:4, 397-401, Oct. 1982. \n46-The value of the laparoscope in the diagnosis of polycystic ovary. Al-Azhar Medical Journal, 11:2, 153-159, April 1982. \n47-An anaesthetic approach to the management of eclampsia. Ain Shams Medical Journal, accepted for publication 1981. \n48-Laparoscopy on patients with previous lower abdominal surgery. Fertility management edited by E. Osman and M. Wahba 1981. \n49-Heart diseases with pregnancy. Population Sciences, 11, 121-130, 1981. \n50-A study of the biosocial factors affecting perinatal mortality in an Egyptian maternity hospital. Population Sciences, 6, 71-90, 1981. \n51-Pregnancy Wastage. Journal of the Egypt. Soc. of Ob./Gyn. 11:3, 57-67, Sept. 1980. \n52-Analysis of maternal deaths in Egyptian maternity hospitals. Population Sciences, 1, 59-65, 1979. \nArticles published on OBGYN.net: \n1- Abdel Karim M. El Hemaly*, Ibrahim M. Kandil, Laila A. S. Mousa and Mohamad A.K.M.El Hemaly.\nUrethro-vaginoplasty, an innovated operation for the treatment of: Stress Urinary Incontinence (SUI), Detursor Overactivity (DO), Mixed Urinary Incontinence and Anterior Vaginal Wall Descent. \nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/ urethro-vaginoplasty_01\n\n2- Abdel Karim M. El Hemaly, Ibrahim M Kandil, Mohamed M. Radwan.\n Urethro-raphy a new technique for surgical management of Stress Urinary Incontinence.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/\nnew-tech-urethro\n\n3- Abdel Karim M. El Hemaly, Ibrahim M Kandil, Mohamad A. Rizk, Nabil Abdel Maksoud H., Mohamad M. Radwan, Khalid Z. El Shieka, Mohamad A. K. M. El Hemaly, and Ahmad T. El Saban.\nUrethro-raphy The New Operation for the treatment of stress urinary incontinence, SUI, detrusor instability, DI, and mixed-type of urinary incontinence; short and long term results. \nhttp://www.obgyn.net/urogyn/urogyn.asp?page=urogyn/articles/\nurethroraphy-09280\n\n4-Abdel Karim M. El Hemaly, Ibrahim M Kandil, and Bahaa E. El Mohamady. Menopause, and Voiding troubles. \nhttp://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly03/el-hemaly03-ss\n\n5-El Hemaly AKMA, Mousa L.A. Micturition and Urinary\tContinence. Int J Gynecol Obstet 1996; 42: 291-2. \n\n6-Abdel Karim M. El Hemaly.\n Urinary incontinence in gynecology, a review article.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/abs-urinary_incotinence_gyn_ehemaly \n\n7-El Hemaly AKMA. Nocturnal Enuresis: Pathogenesis and Treatment. \nInt Urogynecol J Pelvic Floor Dysfunct 1998;9: 129-31.\n \n8-El Hemaly AKMA, Mousa L.A.E. Stress Urinary Incontinence, a New Concept. Eur J Obstet Gynecol Reprod Biol 1996; 68: 129-35. \n\n9- El Hemaly AKMA, Kandil I. M. Stress Urinary Incontinence SUI facts and fiction. Is SUI a puzzle?! http://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly/el-hemaly-ss\n\n10-Abdel Karim El Hemaly, Nabil Abdel Maksoud, Laila A. Mousa, Ibrahim M. Kandil, Asem Anwar, M.A.K El Hemaly and Bahaa E. El Mohamady. \nEvidence based Facts on the Pathogenesis and Management of SUI. http://www.obgyn.net/displayppt.asp?page=/English/pubs/features/presentations/El-Hemaly02/el-hemaly02-ss\n\n11- Abdel Karim M. El Hemaly*, Ibrahim M. Kandil, Mohamad A. Rizk and Mohamad A.K.M.El Hemaly.\n Urethro-plasty, a Novel Operation based on a New Concept, for the Treatment of Stress Urinary Incontinence, S.U.I., Detrusor Instability, D.I., and Mixed-type of Urinary Incontinence.\nhttp://www.obgyn.net/urogyn/urogyn.asp?page=/urogyn/articles/urethro-plasty_01\n\n12-Ibrahim M. Kandil, Abdel Karim M. El Hemaly, Mohamad M. Radwan: Ultrasonic Assessment of the Internal Urethral Sphincter in Stress Urinary Incontinence. The Internet Journal of Gynecology and Obstetrics. 2003. Volume 2 Number 1. \n\n13-Abdel Karim M. El Hemaly. Nocturnal Enureses: A Novel Concept on its pathogenesis and Treatment.\nhttp://www.obgyn.net/urogynecolgy/?page=articles/nocturnal_enuresis\n\n14- Abdel Karim M. El Hemaly. Nocturnal Enureses: An Update on the pathogenesis and Treatment.\nhttp://www.obgyn.net/urogynecology/?page=/ENHLIDH/PUBD/FEATURES/\nPresentations/ Nocturnal_Enuresis/nocturnal_enuresis",institutionString:null,institution:{name:"Al Azhar University",country:{name:"Egypt"}}},{id:"113313",title:"Dr.",name:"Abdel-Aal",middleName:null,surname:"Mantawy",slug:"abdel-aal-mantawy",fullName:"Abdel-Aal Mantawy",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Ain Shams University",country:{name:"Egypt"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5681},{group:"region",caption:"Middle and South America",value:2,count:5161},{group:"region",caption:"Africa",value:3,count:1683},{group:"region",caption:"Asia",value:4,count:10200},{group:"region",caption:"Australia and Oceania",value:5,count:886},{group:"region",caption:"Europe",value:6,count:15610}],offset:12,limit:12,total:1683},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{hasNoEditors:"1",sort:"dateEndThirdStepPublish",topicId:"6,13,16"},books:[{type:"book",id:"10231",title:"Proton Therapy",subtitle:null,isOpenForSubmission:!0,hash:"f4a9009287953c8d1d89f0fa9b7597b0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10231.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10707",title:"Primary Care",subtitle:null,isOpenForSubmission:!0,hash:"bdb1aeb61b1eb116c1bdb09d25593686",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10707.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10715",title:"Brain MRI",subtitle:null,isOpenForSubmission:!0,hash:"6d56c88c53776966959f41f8b75daafd",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10715.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10723",title:"Brachial Plexus Injury",subtitle:null,isOpenForSubmission:!0,hash:"441fb315d751efcdc4ae3fdb03808b46",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10723.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10731",title:"Cannabinoids",subtitle:null,isOpenForSubmission:!0,hash:"1d2e090ecf2415b8d3c9fba15856b7b1",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10731.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10747",title:"Parvoviridae",subtitle:null,isOpenForSubmission:!0,hash:"694a3c1bc3af4d00d994fc83b527eacc",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10747.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10712",title:"Thrombectomy",subtitle:null,isOpenForSubmission:!0,hash:"853e71d74c3dd5007277d3770e639d47",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10712.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10721",title:"Preeclampsia",subtitle:null,isOpenForSubmission:!0,hash:"d23fca4321fbc65c3e5c3e0d377c6e1f",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10721.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10729",title:"Sepsis",subtitle:null,isOpenForSubmission:!0,hash:"3981e82a4ab305272c07784a8f7298fb",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10729.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10745",title:"Nematodes",subtitle:null,isOpenForSubmission:!0,hash:"3b04a8befc32e564599c44178d8a8152",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10745.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10708",title:"Regional Anesthesia",subtitle:null,isOpenForSubmission:!0,hash:"b481b3c45dfcce8c4f048ce08f520763",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10708.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10717",title:"Gestational Diabetes",subtitle:null,isOpenForSubmission:!0,hash:"9e38724c0e4f2bd852444e9b6f0facc8",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10717.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:16},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:9},{group:"topic",caption:"Business, Management and Economics",value:7,count:8},{group:"topic",caption:"Chemistry",value:8,count:4},{group:"topic",caption:"Computer and Information Science",value:9,count:9},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:13},{group:"topic",caption:"Environmental Sciences",value:12,count:6},{group:"topic",caption:"Immunology and Microbiology",value:13,count:7},{group:"topic",caption:"Materials Science",value:14,count:2},{group:"topic",caption:"Mathematics",value:15,count:2},{group:"topic",caption:"Medicine",value:16,count:45},{group:"topic",caption:"Nanotechnology and Nanomaterials",value:17,count:1},{group:"topic",caption:"Neuroscience",value:18,count:3},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:4},{group:"topic",caption:"Social Sciences",value:23,count:6},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:61},popularBooks:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9279",title:"Concepts, Applications and Emerging Opportunities in Industrial Engineering",subtitle:null,isOpenForSubmission:!1,hash:"9bfa87f9b627a5468b7c1e30b0eea07a",slug:"concepts-applications-and-emerging-opportunities-in-industrial-engineering",bookSignature:"Gary Moynihan",coverURL:"https://cdn.intechopen.com/books/images_new/9279.jpg",editors:[{id:"16974",title:"Dr.",name:"Gary",middleName:null,surname:"Moynihan",slug:"gary-moynihan",fullName:"Gary Moynihan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7807",title:"A Closer Look at Organizational Culture in Action",subtitle:null,isOpenForSubmission:!1,hash:"05c608b9271cc2bc711f4b28748b247b",slug:"a-closer-look-at-organizational-culture-in-action",bookSignature:"Süleyman Davut Göker",coverURL:"https://cdn.intechopen.com/books/images_new/7807.jpg",editors:[{id:"190035",title:"Associate Prof.",name:"Süleyman Davut",middleName:null,surname:"Göker",slug:"suleyman-davut-goker",fullName:"Süleyman Davut Göker"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5126},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9376",title:"Contemporary Developments and Perspectives in International Health Security",subtitle:"Volume 1",isOpenForSubmission:!1,hash:"b9a00b84cd04aae458fb1d6c65795601",slug:"contemporary-developments-and-perspectives-in-international-health-security-volume-1",bookSignature:"Stanislaw P. Stawicki, Michael S. Firstenberg, Sagar C. Galwankar, Ricardo Izurieta and Thomas Papadimos",coverURL:"https://cdn.intechopen.com/books/images_new/9376.jpg",editors:[{id:"181694",title:"Dr.",name:"Stanislaw P.",middleName:null,surname:"Stawicki",slug:"stanislaw-p.-stawicki",fullName:"Stanislaw P. Stawicki"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7769",title:"Medical Isotopes",subtitle:null,isOpenForSubmission:!1,hash:"f8d3c5a6c9a42398e56b4e82264753f7",slug:"medical-isotopes",bookSignature:"Syed Ali Raza Naqvi and Muhammad Babar Imrani",coverURL:"https://cdn.intechopen.com/books/images_new/7769.jpg",editors:[{id:"259190",title:"Dr.",name:"Syed Ali Raza",middleName:null,surname:"Naqvi",slug:"syed-ali-raza-naqvi",fullName:"Syed Ali Raza Naqvi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"8468",title:"Sheep Farming",subtitle:"An Approach to Feed, Growth and Sanity",isOpenForSubmission:!1,hash:"838f08594850bc04aa14ec873ed1b96f",slug:"sheep-farming-an-approach-to-feed-growth-and-sanity",bookSignature:"António Monteiro",coverURL:"https://cdn.intechopen.com/books/images_new/8468.jpg",editedByType:"Edited by",editors:[{id:"190314",title:"Prof.",name:"António",middleName:"Cardoso",surname:"Monteiro",slug:"antonio-monteiro",fullName:"António Monteiro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9523",title:"Oral and Maxillofacial Surgery",subtitle:null,isOpenForSubmission:!1,hash:"5eb6ec2db961a6c8965d11180a58d5c1",slug:"oral-and-maxillofacial-surgery",bookSignature:"Gokul Sridharan",coverURL:"https://cdn.intechopen.com/books/images_new/9523.jpg",editedByType:"Edited by",editors:[{id:"82453",title:"Dr.",name:"Gokul",middleName:null,surname:"Sridharan",slug:"gokul-sridharan",fullName:"Gokul Sridharan"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9785",title:"Endometriosis",subtitle:null,isOpenForSubmission:!1,hash:"f457ca61f29cf7e8bc191732c50bb0ce",slug:"endometriosis",bookSignature:"Courtney Marsh",coverURL:"https://cdn.intechopen.com/books/images_new/9785.jpg",editedByType:"Edited by",editors:[{id:"255491",title:"Dr.",name:"Courtney",middleName:null,surname:"Marsh",slug:"courtney-marsh",fullName:"Courtney Marsh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9018",title:"Some RNA Viruses",subtitle:null,isOpenForSubmission:!1,hash:"a5cae846dbe3692495fc4add2f60fd84",slug:"some-rna-viruses",bookSignature:"Yogendra Shah and Eltayb Abuelzein",coverURL:"https://cdn.intechopen.com/books/images_new/9018.jpg",editedByType:"Edited by",editors:[{id:"278914",title:"Ph.D.",name:"Yogendra",middleName:null,surname:"Shah",slug:"yogendra-shah",fullName:"Yogendra Shah"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8816",title:"Financial Crises",subtitle:"A Selection of Readings",isOpenForSubmission:!1,hash:"6f2f49fb903656e4e54280c79fabd10c",slug:"financial-crises-a-selection-of-readings",bookSignature:"Stelios Markoulis",coverURL:"https://cdn.intechopen.com/books/images_new/8816.jpg",editedByType:"Edited by",editors:[{id:"237863",title:"Dr.",name:"Stelios",middleName:null,surname:"Markoulis",slug:"stelios-markoulis",fullName:"Stelios Markoulis"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9585",title:"Advances in Complex Valvular Disease",subtitle:null,isOpenForSubmission:!1,hash:"ef64f11e211621ecfe69c46e60e7ca3d",slug:"advances-in-complex-valvular-disease",bookSignature:"Michael S. Firstenberg and Imran Khan",coverURL:"https://cdn.intechopen.com/books/images_new/9585.jpg",editedByType:"Edited by",editors:[{id:"64343",title:null,name:"Michael S.",middleName:"S",surname:"Firstenberg",slug:"michael-s.-firstenberg",fullName:"Michael S. Firstenberg"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10150",title:"Smart Manufacturing",subtitle:"When Artificial Intelligence Meets the Internet of Things",isOpenForSubmission:!1,hash:"87004a19de13702d042f8ff96d454698",slug:"smart-manufacturing-when-artificial-intelligence-meets-the-internet-of-things",bookSignature:"Tan Yen Kheng",coverURL:"https://cdn.intechopen.com/books/images_new/10150.jpg",editedByType:"Edited by",editors:[{id:"78857",title:"Dr.",name:"Tan Yen",middleName:null,surname:"Kheng",slug:"tan-yen-kheng",fullName:"Tan Yen Kheng"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9386",title:"Direct Numerical Simulations",subtitle:"An Introduction and Applications",isOpenForSubmission:!1,hash:"158a3a0fdba295d21ff23326f5a072d5",slug:"direct-numerical-simulations-an-introduction-and-applications",bookSignature:"Srinivasa Rao",coverURL:"https://cdn.intechopen.com/books/images_new/9386.jpg",editedByType:"Edited by",editors:[{id:"6897",title:"Dr.",name:"Srinivasa",middleName:"P",surname:"Rao",slug:"srinivasa-rao",fullName:"Srinivasa Rao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editedByType:"Edited by",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editedByType:"Edited by",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"387",title:"Biotechnology",slug:"biochemistry-genetics-and-molecular-biology-bromatology-biotechnology",parent:{title:"Bromatology",slug:"biochemistry-genetics-and-molecular-biology-bromatology"},numberOfBooks:1,numberOfAuthorsAndEditors:61,numberOfWosCitations:131,numberOfCrossrefCitations:49,numberOfDimensionsCitations:142,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"biochemistry-genetics-and-molecular-biology-bromatology-biotechnology",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"1484",title:"Soybean",subtitle:"Molecular Aspects of Breeding",isOpenForSubmission:!1,hash:"3bd8fd078e7df24f2eed6dc7bc226475",slug:"soybean-molecular-aspects-of-breeding",bookSignature:"Aleksandra Sudaric",coverURL:"https://cdn.intechopen.com/books/images_new/1484.jpg",editedByType:"Edited by",editors:[{id:"21485",title:"Dr.",name:"Aleksandra",middleName:null,surname:"Sudarić",slug:"aleksandra-sudaric",fullName:"Aleksandra Sudarić"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:1,mostCitedChapters:[{id:"14941",doi:"10.5772/14407",title:"Evolution of Soybean Aphid Biotypes: Understanding and Managing Virulence to Host-Plant Resistance",slug:"evolution-of-soybean-aphid-biotypes-understanding-and-managing-virulence-to-host-plant-resistance",totalDownloads:2932,totalCrossrefCites:2,totalDimensionsCites:33,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Andrew P. Michel, Omprakash Mittapalli and M. A. Rouf Mian",authors:[{id:"17721",title:"Dr.",name:"Andrew P.",middleName:null,surname:"Michel",slug:"andrew-p.-michel",fullName:"Andrew P. Michel"},{id:"22017",title:"Dr.",name:"Omprakash",middleName:null,surname:"Mittapalli",slug:"omprakash-mittapalli",fullName:"Omprakash Mittapalli"},{id:"22018",title:"Dr.",name:"M. A. Rouf",middleName:null,surname:"Mian",slug:"m.-a.-rouf-mian",fullName:"M. A. Rouf Mian"}]},{id:"14938",doi:"10.5772/15688",title:"Phomopsis Seed Decay of Soybean",slug:"phomopsis-seed-decay-of-soybean",totalDownloads:4206,totalCrossrefCites:6,totalDimensionsCites:16,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Shuxian Li",authors:[{id:"21619",title:"Dr.",name:"Shuxian",middleName:null,surname:"Li",slug:"shuxian-li",fullName:"Shuxian Li"}]},{id:"14933",doi:"10.5772/14533",title:"Breeding for Promiscuous Soybeans at IITA",slug:"breeding-for-promiscuous-soybeans-at-iita",totalDownloads:3237,totalCrossrefCites:5,totalDimensionsCites:14,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Hailu Tefera",authors:[{id:"18065",title:"Dr.",name:"Hailu",middleName:null,surname:"Tefera",slug:"hailu-tefera",fullName:"Hailu Tefera"}]}],mostDownloadedChaptersLast30Days:[{id:"14938",title:"Phomopsis Seed Decay of Soybean",slug:"phomopsis-seed-decay-of-soybean",totalDownloads:4206,totalCrossrefCites:6,totalDimensionsCites:16,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Shuxian Li",authors:[{id:"21619",title:"Dr.",name:"Shuxian",middleName:null,surname:"Li",slug:"shuxian-li",fullName:"Shuxian Li"}]},{id:"14939",title:"Soybean Rust: Five Years of Research",slug:"soybean-rust-five-years-of-research",totalDownloads:2875,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Arianne Tremblay",authors:[{id:"19754",title:"Dr.",name:"Arianne",middleName:null,surname:"Tremblay",slug:"arianne-tremblay",fullName:"Arianne Tremblay"}]},{id:"14931",title:"Integration of Major QTLs of Important Agronomic Traits in Soybean",slug:"integration-of-major-qtls-of-important-agronomic-traits-in-soybean",totalDownloads:2881,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Guohua Hu, Qingshan Chen, Chunyan Liu, Hongwei Jiang, Jialin Wang and Zhaoming Qi",authors:[{id:"17679",title:"Dr.",name:"Guo-Hua",middleName:null,surname:"Hu",slug:"guo-hua-hu",fullName:"Guo-Hua Hu"},{id:"17680",title:"PhD.",name:"Jialin",middleName:null,surname:"Wang",slug:"jialin-wang",fullName:"Jialin Wang"},{id:"21219",title:"Dr.",name:"Qingshan",middleName:null,surname:"Chen",slug:"qingshan-chen",fullName:"Qingshan Chen"},{id:"21220",title:"Dr.",name:"Chunyan",middleName:null,surname:"Liu",slug:"chunyan-liu",fullName:"Chunyan Liu"},{id:"21221",title:"PhD.",name:"Hongwei",middleName:null,surname:"Jiang",slug:"hongwei-jiang",fullName:"Hongwei Jiang"},{id:"21222",title:"Dr.",name:"Rongsheng",middleName:null,surname:"Zhu",slug:"rongsheng-zhu",fullName:"Rongsheng Zhu"},{id:"21223",title:"Mr.",name:"Zhenbang",middleName:null,surname:"Hu",slug:"zhenbang-hu",fullName:"Zhenbang Hu"},{id:"21224",title:"Dr.",name:"Zhaoming",middleName:null,surname:"Qi",slug:"zhaoming-qi",fullName:"Zhaoming Qi"}]},{id:"14941",title:"Evolution of Soybean Aphid Biotypes: Understanding and Managing Virulence to Host-Plant Resistance",slug:"evolution-of-soybean-aphid-biotypes-understanding-and-managing-virulence-to-host-plant-resistance",totalDownloads:2932,totalCrossrefCites:2,totalDimensionsCites:33,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Andrew P. Michel, Omprakash Mittapalli and M. A. Rouf Mian",authors:[{id:"17721",title:"Dr.",name:"Andrew P.",middleName:null,surname:"Michel",slug:"andrew-p.-michel",fullName:"Andrew P. Michel"},{id:"22017",title:"Dr.",name:"Omprakash",middleName:null,surname:"Mittapalli",slug:"omprakash-mittapalli",fullName:"Omprakash Mittapalli"},{id:"22018",title:"Dr.",name:"M. A. Rouf",middleName:null,surname:"Mian",slug:"m.-a.-rouf-mian",fullName:"M. A. Rouf Mian"}]},{id:"14927",title:"Protein Expression Systems: Why Soybean Seeds?",slug:"protein-expression-systems-why-soybean-seeds-",totalDownloads:2202,totalCrossrefCites:3,totalDimensionsCites:7,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Kenneth Bost and Kenneth Piller",authors:[{id:"19743",title:"Dr.",name:"Kenneth J.",middleName:null,surname:"Piller",slug:"kenneth-j.-piller",fullName:"Kenneth J. Piller"},{id:"20579",title:"Dr.",name:"Kenneth L.",middleName:null,surname:"Bost",slug:"kenneth-l.-bost",fullName:"Kenneth L. Bost"}]},{id:"14928",title:"Optimizing Recombinant Protein Expression in Soybean",slug:"optimizing-recombinant-protein-expression-in-soybean",totalDownloads:2766,totalCrossrefCites:1,totalDimensionsCites:4,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Laura C. Hudson, Kenneth L. Bost and Kenneth J. Piller",authors:[{id:"19743",title:"Dr.",name:"Kenneth J.",middleName:null,surname:"Piller",slug:"kenneth-j.-piller",fullName:"Kenneth J. Piller"},{id:"20579",title:"Dr.",name:"Kenneth L.",middleName:null,surname:"Bost",slug:"kenneth-l.-bost",fullName:"Kenneth L. Bost"},{id:"22101",title:"Dr.",name:"Laura C.",middleName:null,surname:"Hudson",slug:"laura-c.-hudson",fullName:"Laura C. Hudson"}]},{id:"14932",title:"A Versatile Soybean Recombinant Inbred Line Population Segregating for Low Linolenic Acid and Lipoxygenase Nulls - Molecular Characterization and Utility for Soymilk and Bioproduct Production",slug:"a-versatile-soybean-recombinant-inbred-line-population-segregating-for-low-linolenic-acid-and-lipoxy",totalDownloads:1977,totalCrossrefCites:1,totalDimensionsCites:2,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Yarmilla Reinprecht, Shun-Yan Luk-Labey and K. Peter Pauls",authors:[{id:"21285",title:"Dr.",name:"Karl Peter",middleName:null,surname:"Pauls",slug:"karl-peter-pauls",fullName:"Karl Peter Pauls"},{id:"21286",title:"Dr.",name:"Yarmilla",middleName:null,surname:"Reinprecht",slug:"yarmilla-reinprecht",fullName:"Yarmilla Reinprecht"}]},{id:"14945",title:"Spectral Characteristics of Soybean during the Vegetative Cycle Using Landsat 5/TM Images in The Western Paraná, Brazil",slug:"spectral-characteristics-of-soybean-during-the-vegetative-cycle-using-landsat-5-tm-images-in-the-wes",totalDownloads:2128,totalCrossrefCites:0,totalDimensionsCites:1,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Erivelto Mercante, Rubens A. C. Lamparelli, Miguel A. Uribe-Opazo and Jansle Viera Rocha",authors:[{id:"17800",title:"Dr.",name:"Erivelto",middleName:null,surname:"Mercante",slug:"erivelto-mercante",fullName:"Erivelto Mercante"},{id:"17931",title:"Dr.",name:"Rubens A. C.",middleName:null,surname:"Lamparelli",slug:"rubens-a.-c.-lamparelli",fullName:"Rubens A. C. Lamparelli"},{id:"17932",title:"Dr.",name:"Miguel Angel",middleName:null,surname:"Uribe-Opazo",slug:"miguel-angel-uribe-opazo",fullName:"Miguel Angel Uribe-Opazo"},{id:"17933",title:"Dr.",name:"Jansle Viera",middleName:null,surname:"Rocha",slug:"jansle-viera-rocha",fullName:"Jansle Viera Rocha"}]},{id:"14935",title:"Proteomics Approach for Identifying Abiotic Stress Responsive Proteins in Soybean",slug:"proteomics-approach-for-identifying-abiotic-stress-responsive-proteins-in-soybean",totalDownloads:4116,totalCrossrefCites:4,totalDimensionsCites:13,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Mohammad-Zaman Nouri, Mahmoud Toorchi and Setsuko Komatsu",authors:[{id:"21116",title:"Dr.",name:"Setsuko",middleName:null,surname:"Komatsu",slug:"setsuko-komatsu",fullName:"Setsuko Komatsu"},{id:"21118",title:"Mr.",name:"Mohammad-Zaman",middleName:null,surname:"Nouri",slug:"mohammad-zaman-nouri",fullName:"Mohammad-Zaman Nouri"},{id:"21119",title:"Dr.",name:"Mahmoud",middleName:null,surname:"Toorchi",slug:"mahmoud-toorchi",fullName:"Mahmoud Toorchi"}]},{id:"14929",title:"Virus-Induced Gene Silencing of Endogenous Genes and Promotion of Flowering in Soybean by Apple latent spherical virus-Based Vectors",slug:"virus-induced-gene-silencing-of-endogenous-genes-and-promotion-of-flowering-in-soybean-by-apple-late",totalDownloads:2744,totalCrossrefCites:4,totalDimensionsCites:10,book:{slug:"soybean-molecular-aspects-of-breeding",title:"Soybean",fullTitle:"Soybean - Molecular Aspects of Breeding"},signatures:"Noriko Yamagishi and Nobuyuki Yoshikawa",authors:[{id:"18191",title:"Dr.",name:"Nobuyuki",middleName:null,surname:"Yoshikawa",slug:"nobuyuki-yoshikawa",fullName:"Nobuyuki Yoshikawa"},{id:"21453",title:"Dr.",name:"Noriko",middleName:null,surname:"Yamagishi",slug:"noriko-yamagishi",fullName:"Noriko Yamagishi"}]}],onlineFirstChaptersFilter:{topicSlug:"biochemistry-genetics-and-molecular-biology-bromatology-biotechnology",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"chapter.detail",path:"/books/drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications/salicylic-acid-sans-aspirin-in-animals-and-man",hash:"",query:{},params:{book:"drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications",chapter:"salicylic-acid-sans-aspirin-in-animals-and-man"},fullPath:"/books/drug-repurposing-hypothesis-molecular-aspects-and-therapeutic-applications/salicylic-acid-sans-aspirin-in-animals-and-man",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()